
NRXBF
Healthcare · Biotechnology · $31.8M market cap
$0.3353-0.01 (-3.1%)Nov 13, 3:49 PM EST
Latest report
Before the open
The next earnings date isn’t on the calendar yet.
Analyst consensus
Fiscal period ending Sep 30, 2026
EPS trend, 90 days to now · 0.0% over 90 days · 30-day revisions 1 up, 0 down
Beat estimates in 0 of the last 4 reported quarters.
EPS surprise versus the estimate at the time of the report.
| Date | Session | Estimate | Actual | Surprise |
|---|---|---|---|---|
| Aug 26, 2026 | Before the open | -0.02 | -0.02 | 0.0% |
| Apr 16, 2026 | Before the open | -0.02 | -0.02 | 0.0% |
| Nov 26, 2025 | After the close | -0.02 | -0.02 | 0.0% |
| Aug 27, 2025 | After the close | -0.02 | -0.02 | 0.0% |
| May 27, 2025 | Before the open | -0.02 | -0.02 | 0.0% |
| Nov 27, 2024 | Before the open | -0.03 | -0.02 | +33.3% |
| Aug 27, 2024 | After the close | -0.02 | -0.02 | 0.0% |
| Apr 2, 2024 | Before the open | -0.02 | -0.01 | +50.0% |
| Aug 28, 2023 | Before the open | -0.02 | -0.02 | 0.0% |
NurExone Biologic Inc., a pharmaceutical technology company, develops a platform for biologically guided exosome-based therapies for the treatment of central nervous system injuries. It offers ExoPTEN, for treatment of acute spinal cord injuries. The company was founded in 2020 and is based in Toronto, Canada.